Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Intralase LASIK, results conventional and customized

Poster Details

First Author: T.Gamaly OMAN

Co Author(s):                  

Abstract Details


To analyze the results of IntraLase laser in situ Keratomileusis (IL LASIK) using the femtosecond laser IntraLase & Nidek NAVEX excimer laser system with either the conventional, the Optimized Aspheric Transitional zone (OATz) ablation profile, and the Optical path Difference Customized Aspheric Transitional zone ablation (OPDCAT) ablation profile to correct compound myopic astigmatism.


MAGRABI Eye &Ear Hospitals & Centers, Muscat-OMAN


In a prospective study, the IL LASIK was used to treat patients with compound myopic astigmatism. Either conventional, OATz, or OPDCAT was used to achieve the optimum results. Conventional was performed in 50 eyes of 29 patients, OATZ was performed in 84 eyes of 47 patients, and OPDCAT was performed in 8 eyes of 6 patients. All eyes were measured by the Nidek OPD-Scan II. Data of eyes with OATz and OPDCAT were imported to Final Fit software. Eyes were treated with optical zone of at least 5.00 mm, and a transitional zone of maximum 9.00 mm. TED and OTE was used in cases of OATz & OPDCAT. Uncorrected spectacle visual acuity (UCVA), refraction, and subjective evaluation of glare and night vision by questionnaire were recorded after surgery.


Mean follow-up was 12 months. At baseline, the mean preoperative spherical equivalent and range for each group was measured. At last follow-up, UCVA, refraction and BSCVA were measured. No patient reported significant glare or night vision problems on subjective questionnaire.


IL LASIK and the Nidek NAVEX system were safe, effective and predictable in correcting compound myopic astigmatism in all profiles. In both the OATz & OPDCAT ablation profile, patients were satisfied with their quality of vision. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.